title: Impact of germline and somatic missense variations on drug binding sites.
abstract: Advancements in next-generation sequencing (NGS) technologies are generating a vast amount of data. This exacerbates the current challenge of translating NGS data into actionable clinical interpretations. We have comprehensively combined germline and somatic nonsynonymous single-nucleotide variations (nsSNVs) that affect drug binding sites in order to investigate their prevalence. The integrated data thus generated in conjunction with exome or whole-genome sequencing can be used to identify patients who may not respond to a specific drug because of alterations in drug binding efficacy due to nsSNVs in the target protein's gene. To identify the nsSNVs that may affect drug binding, protein-drug complex structures were retrieved from Protein Data Bank (PDB) followed by identification of amino acids in the protein-drug binding sites using an occluded surface method. Then, the germline and somatic mutations were mapped to these amino acids to identify which of these alter protein-drug binding sites. Using this method we identified 12 993 amino acid-drug binding sites across 253 unique proteins bound to 235 unique drugs. The integration of amino acid-drug binding sites data with both germline and somatic nsSNVs data sets revealed 3133 nsSNVs affecting amino acid-drug binding sites. In addition, a comprehensive drug target discovery was conducted based on protein structure similarity and conservation of amino acid-drug binding sites. Using this method, 81 paralogs were identified that could serve as alternative drug targets. In addition, non-human mammalian proteins bound to drugs were used to identify 142 homologs in humans that can potentially bind to drugs. In the current protein-drug pairs that contain somatic mutations within their binding site, we identified 85 proteins with significant differential gene expression changes associated with specific cancer types. Information on protein-drug binding predicted drug target proteins and prevalence of both somatic and germline nsSNVs that disrupt these binding sites can provide valuable knowledge for personalized medicine treatment. A web portal is available where nsSNVs from individual patient can be checked by scanning against DrugVar to determine whether any of the SNVs affect the binding of any drug in the database.
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.
authors.forename: C
authors.initials: C
authors.lastname: Yan
authors.affiliation: MolBox LLC, Silver Spring, MD, USA.
authors.forename: N
authors.initials: N
authors.lastname: Pattabiraman
authors.affiliation: The Computational Biology Institute, George Washington University, Ashburn, VA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Goecks
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.
authors.forename: P
authors.initials: P
authors.lastname: Lam
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.
authors.forename: A
authors.initials: A
authors.lastname: Nayak
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Pan
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.
authors.forename: J
authors.initials: J
authors.lastname: Torcivia-Rodriguez
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.
authors.forename: A
authors.initials: A
authors.lastname: Voskanian
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Wan
authors.affiliation: Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.|McCormick Genomic and Proteomic Center, George Washington University, Washington, DC, USA.
authors.forename: R
authors.initials: R
authors.lastname: Mazumder
mesh_terms: D000818:Animals; D001665:Binding Sites; D019295:Computational Biology; D057225:Data Mining; D030541:Databases, Genetic; D005838:Genotype; D018095:Germ-Line Mutation; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008958:Models, Molecular; D020125:Mutation, Missense; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000378:metabolism*; D010597:Pharmacogenetics / Q000379:methods*; D000071184:Pharmacogenomic Variants; D010641:Phenotype; D057285:Precision Medicine; D011485:Protein Binding; D011487:Protein Conformation; D013329:Structure-Activity Relationship; D018511:Systems Integration
chemical_list: D004364:Pharmaceutical Preparations
references.citation: Therapie. 2007 Mar-Apr;62(2):87-90
references.pmid: 17582306
references.citation: Mutagenesis. 2014 Sep;29(5):303-10
references.pmid: 25150023
references.citation: Chem Biol Drug Des. 2009 Nov;74(5):457-67
references.pmid: 19811506
references.citation: Neuroscience. 2007 Apr 14;145(4):1273-9
references.pmid: 17055652
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002
references.pmid: 14967461
references.citation: Clin Lab Med. 2012 Dec;32(4):585-99
references.pmid: 23078661
references.citation: Hum Mol Genet. 2007 Jun 1;16(11):1367-80
references.pmid: 17412754
references.citation: Clin Pharmacol Ther. 2012 Oct;92(4):414-7
references.pmid: 22992668
references.citation: PLoS Comput Biol. 2008 Sep 26;4(9):e1000151
references.pmid: 18818720
references.citation: Clin Cancer Res. 2000 May;6(5):2053-63
references.pmid: 10815932
references.citation: J Clin Oncol. 2005 Feb 10;23 (5):939-52
references.pmid: 15557593
references.citation: Methods Mol Biol. 2009;563:123-40
references.pmid: 19597783
references.citation: Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53
references.pmid: 12571811
references.citation: Database (Oxford). 2014 Mar 25;2014:bau022
references.pmid: 24667251
references.citation: Int J Mol Med. 2003 Mar;11(3):379-82
references.pmid: 12579344
references.citation: Pharmacogenomics. 2010 Apr;11(4):501-5
references.pmid: 20350130
references.citation: Nucleic Acids Res. 2002 Sep 1;30(17):3894-900
references.pmid: 12202775
references.citation: Nature. 2010 Apr 15;464(7291):993-8
references.pmid: 20393554
references.citation: Pharmacol Rev. 2011 Jun;63(2):437-59
references.pmid: 21436344
references.citation: Genome Res. 2009 Sep;19(9):1639-45
references.pmid: 19541911
references.citation: Genome Biol. 2010;11(10):R106
references.pmid: 20979621
references.citation: J Genet Genomics. 2011 Mar 20;38(3):95-109
references.pmid: 21477781
references.citation: Pharmacology. 2008;81(1):11-7
references.pmid: 17726343
references.citation: Int J Clin Pract. 2004 May;58(5):511-6
references.pmid: 15206509
references.citation: Nucleic Acids Res. 2001 Jan 1;29(1):308-11
references.pmid: 11125122
references.citation: Clin Pharmacol Ther. 2007 Mar;81(3):328-45
references.pmid: 17339863
references.citation: Acta Crystallogr D Biol Crystallogr. 2002 Jun;58(Pt 6 No 1):899-907
references.pmid: 12037327
references.citation: Q Rev Biophys. 2012 Nov;45(4):383-426
references.pmid: 22971516
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5465-76
references.pmid: 14654525
references.citation: J Comput Chem. 2004 Oct;25(13):1605-12
references.pmid: 15264254
references.citation: Biochemistry. 2010 Jun 29;49(25):5340-9
references.pmid: 20462199
references.citation: Cancer Res. 2005 Jul 1;65(13):5711-9
references.pmid: 15994946
references.citation: Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41
references.pmid: 21059682
references.citation: Blood. 2006 Jun 1;107(11):4334-7
references.pmid: 16449525
references.citation: Nat Methods. 2013 Nov;10(11):1081-2
references.pmid: 24037244
references.citation: Expert Opin Pharmacother. 2005 Dec;6(15):2565-76
references.pmid: 16316297
references.citation: Science. 1999 Oct 15;286(5439):487-91
references.pmid: 10521338
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1630-8
references.pmid: 16533791
references.citation: Curr Pharm Des. 2008;14(7):649-54
references.pmid: 18336310
references.citation: J Clin Oncol. 2007 Mar 20;25(9):1146-7; author reply 1147-8
references.pmid: 17369583
references.citation: Recent Results Cancer Res. 2010;184:3-20
references.pmid: 20072827
references.citation: Bioinformatics. 2011 Apr 15;27(8):1190-1
references.pmid: 21478197
references.citation: Cancer Invest. 2003;21(4):630-40
references.pmid: 14533451
references.citation: Database (Oxford). 2015 Mar 28;2015:null
references.pmid: 25819073
references.citation: Clin Ther. 2009;31 Pt 2:2332-48
references.pmid: 20110044
references.citation: Thromb Haemost. 2013 Nov;110(5):876-87
references.pmid: 23702580
references.citation: Curr Top Med Chem. 2007;7(9):825-33
references.pmid: 17504127
references.citation: Nucleic Acids Res. 2015 Jan;43(Database issue):D345-56
references.pmid: 25428375
references.citation: Curr Protoc Bioinformatics. 2006 Oct;Chapter 5:Unit 5.6
references.pmid: 18428767
references.citation: Clin Ther. 2008 Aug;30(8):1426-47
references.pmid: 18803986
references.citation: Asian Pac J Trop Med. 2014 Jul;7(7):513-6
references.pmid: 25063278
references.citation: Nucleic Acids Res. 2014 Oct;42(18):11570-88
references.pmid: 25232094
references.citation: Blood. 2005 Oct 15;106(8):2865-70
references.pmid: 15972446
references.citation: J Neural Transm (Vienna). 2015 Jan;122(1):29-34
references.pmid: 25150845
references.citation: BMC Bioinformatics. 2014 Jan 27;15:28
references.pmid: 24467687
references.citation: Database (Oxford). 2013 Jul 18;2013:bat049
references.pmid: 23868908
references.citation: Cancer Res. 2013 Jul 15;73(14):4372-82
references.pmid: 23856246
references.citation: Curr Med Chem Anticancer Agents. 2004 Jan;4(1):1-17
references.pmid: 14754408
references.citation: Surgery. 2006 Jun;139(6):806-14
references.pmid: 16782438
references.citation: Nat Genet. 2003 Mar;33 Suppl:219-27
references.pmid: 12610531
references.citation: J Chem Inf Model. 2013 Dec 23;53(12):3343-51
references.pmid: 24304102
references.citation: Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7
references.pmid: 24203711
references.citation: Genome Res. 2003 Sep;13(9):2129-41
references.pmid: 12952881
references.citation: BioData Min. 2013 Jul 25;6(1):13
references.pmid: 23885890
references.citation: Dig Dis Sci. 2006 Jun;51(6):1043-6
references.pmid: 16865565
references.citation: Mol Pharmacol. 2006 Nov;70(5):1832-9
references.pmid: 16936229
references.citation: Expert Rev Anticancer Ther. 2003 Jun;3(3):269-79
references.pmid: 12820772
references.citation: Methods Mol Biol. 2008;484:465-90
references.pmid: 18592196
references.citation: Nucleic Acids Res. 2010 Sep;38(16):e164
references.pmid: 20601685
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Nucleic Acids Res. 2015 Jan;43(Database issue):D204-12
references.pmid: 25348405
references.citation: J Med Chem. 2010 Jan 28;53(2):850-4
references.pmid: 20028100
references.citation: Nucleic Acids Res. 1997 Sep 1;25(17):3389-402
references.pmid: 9254694
references.citation: Pharmacogenetics. 1998 Aug;8(4):283-9
references.pmid: 9731714
references.citation: J Mol Recognit. 1995 Nov-Dec;8(6):334-44
references.pmid: 9052974
references.citation: Nucleic Acids Res. 2007 Jan;35(Database issue):D219-23
references.pmid: 17132832
references.citation: Rapid Commun Mass Spectrom. 2005;19(12):1637-43
references.pmid: 15915474